{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=4",
    "query": {
      "intervention": "Placebo for Subcutaneous Injection",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1163,
    "total_pages": 117,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T20:30:26.525Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07226050",
      "title": "CLF065 for Chronic Pouchitis",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pouchitis"
      ],
      "interventions": [
        {
          "name": "CLF065",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calibr, a division of Scripps Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-06-01",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07226050"
    },
    {
      "nct_id": "NCT04213274",
      "title": "Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schnitzler Syndrome",
        "Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)"
      ],
      "interventions": [
        {
          "name": "80 mg RPH-104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "R-Pharm Overseas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-05",
      "completion_date": "2024-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213274"
    },
    {
      "nct_id": "NCT00994110",
      "title": "Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Pasireotide (SOM230)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 439,
      "start_date": "2009-10",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-02-01",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00994110"
    },
    {
      "nct_id": "NCT05154955",
      "title": "A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Submental Fat"
      ],
      "interventions": [
        {
          "name": "10XB-101 Solution for Injection",
          "type": "DRUG"
        },
        {
          "name": "10XB-101 Vehicle Solution for Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "10xBio, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 51,
      "start_date": "2021-10-19",
      "completion_date": "2024-03-19",
      "has_results": false,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 4,
      "location_summary": "Encino, California • San Diego, California • Rolling Meadows, Illinois",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05154955"
    },
    {
      "nct_id": "NCT01605435",
      "title": "Ghrelin Dose Finding In Frail Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "The Frailty Syndrome"
      ],
      "interventions": [
        {
          "name": "Ghrelin Group 1",
          "type": "DRUG"
        },
        {
          "name": "Ghrelin Group 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2012-05",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605435"
    },
    {
      "nct_id": "NCT01055704",
      "title": "Effect of Methylnaltrexone on GI Transit in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gastric Motility Disorder"
      ],
      "interventions": [
        {
          "name": "Methylnaltrexone only",
          "type": "DRUG"
        },
        {
          "name": "Codeine only",
          "type": "DRUG"
        },
        {
          "name": "Methylnaltrexone + codeine",
          "type": "DRUG"
        },
        {
          "name": "Placebo + placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2009-11",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2012-06-25",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01055704"
    },
    {
      "nct_id": "NCT01747538",
      "title": "Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dose 1 gevokizumab",
          "type": "DRUG"
        },
        {
          "name": "Dose 2 gevokizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XOMA (US) LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 281,
      "start_date": "2012-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-12",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 51,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 48 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01747538"
    },
    {
      "nct_id": "NCT02805790",
      "title": "Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Mitochondrial Disease"
      ],
      "interventions": [
        {
          "name": "Elamipretide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2016-08-22",
      "completion_date": "2017-03-23",
      "has_results": true,
      "last_update_posted_date": "2020-07-17",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02805790"
    },
    {
      "nct_id": "NCT03844061",
      "title": "Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo Subcutaneous Injection",
          "type": "OTHER"
        },
        {
          "name": "Placebo Infusion",
          "type": "OTHER"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-07-29",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03844061"
    },
    {
      "nct_id": "NCT03930732",
      "title": "Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Dupilumab SAR231893",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Corticosteroid",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Long-Acting Beta Agonist",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Long-Acting Muscarinic Antagonist",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 939,
      "start_date": "2019-04-15",
      "completion_date": "2023-05-02",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-11-18T20:30:26.525Z",
      "location_count": 51,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03930732"
    }
  ]
}